Table 1.
Patient Characteristics
| Characteristic | All Patients (N=84) |
Myeloid Malignancy (N=49) |
Lymphoid Malignancy (N=35) |
||||
|---|---|---|---|---|---|---|---|
| Age, years | |||||||
| Median | 48.5 | 51 | 43 | p =0.032 | |||
| Range | 18 – 72 | 21 – 72 | 18 – 69 | ||||
| Patients ≥ 60 years old (n, %) | 15 | 17.9% | 11 | 22.5% | 4 | 11.4% | |
| Duration of follow-up, months | |||||||
| Median | 63 | 45.5 | 78 | p =0.008 | |||
| Range | 1 - 113 | 1 - 113 | 5 – 113 | ||||
| Diagnosis | |||||||
| Acute Myeloid Leukemia (AML) | 36 | 42.8% | 36 | 73% | |||
| Myelodysplastic syndrome (MDS) | 13 | 15.5% | 13 | 27% | |||
| Acute Lymphoid Leukemia (ALL) | 12 | 14.1% | 12 | 34.3% | |||
| Hodgkin’s Disease (HD) | 4 | 4.7% | 4 | 11.4% | |||
| Mantle Cell Lymphoma (MCL) | 2 | 2.4% | 2 | 5.7% | |||
| Non Hodgkin’s Lymphoma (NHL) | 17 | 20.0% | 17 | 48.6% | |||
| Pre-transplantation therapies | |||||||
| Prior autologous transplantation | 14 | 16.5% | 8 | 16.0% | 6 | 17.1% | p = 0.89 |
| Prior allogeneic transplantation | 10 | 11.7% | 6 | 12.0% | 4 | 11.4% | p = 0.94 |
| Relapse or Refractory Disease at Transplant |
43 | 50.6% | 23 | 46.0% | 20 | 57.1% | p = 0.43 |